



Ascent

SEPTEMBER | 2018

Please see the Legal Disclaimer about risks and uncertainties at end of presentation


ASCENT | AT A GLANCE

COMPANY	
Exchange	Canadian Securities Exchange
Ticker	ASNT
Headquarters	Vancouver, Canada
Campuses	Canada, USA (2), Denmark
Licences	Canada, Nevada, Oregon

OPERATIONS	
Cultivation Facilities	Canada, Nevada
Cultivation Capacity	65m grams/year
Production Facilities	Canada, Oregon
Production Capacity	12m grams oil/year

FINANCIAL (7 September 2018)	
Shares Outstanding	315m
Shares Fully Diluted	462m
Recent Share Price	\$0.56
Market Cap	\$176m
Enterprise Value	\$151m ¹

(1) Enterprise Value = current market cap + net debt as at time of RTO completion.



Source: The Canadian Stock Exchange

ASCENT | LIVING WHAT WE BELIEVE

OUR MISSION:

THROUGH INNOVATION, VISION AND COMMUNICATION, WE OFFER THE BEST CANNABIS PRODUCTS AND SERVICES TO MEET THE PERSONAL NEEDS OF OUR CUSTOMERS.

OUR VISION:


ENHANCING THE QUALITY OF LIFE OF OTHERS.

OUR FOCUS:

CONSUMER EXPERIENCE, COMMUNITY AND INNOVATION.

ASCENT | POSITIONED FOR GROWTH

Ascent has all the key ingredients to accelerate growth.



ASCENT | AN EXPERIENCED TEAM

Ascent has an experienced, multi-faceted senior management team.



Philip Campbell | Co-Founder,
Chairman, Chief Executive Officer

With an unparalleled level of industry knowledge in the medical and recreational cannabis space both in Canada and the United States, Philip touches all aspects of the Ascent organization and leads in a variety of ways. Having already co-founded a successful entrepreneurial endeavor in the tech space, Philip brings a wealth of expertise to Ascent. Philip holds a Bachelor of Business Administration with a major in Marketing from Simon Fraser University.



Reid Parr | Co-Founder, Director, Chief Operations Officer

Through his 17+ years of industry experience, Reid has been instrumental in cultivating unique opportunities, ensuring operational excellence, and fostering continued growth for Ascent. Reid has extensive experience in all areas of the industry from cultivation and processing to manufacturing, e-commerce, and corporate finance. He possesses a deep passion and keen eye for new technology, products, and strategic partnerships that set Ascent apart from others. He co-founded RPM Web Development Ltd. in 2007 where his company emerged as a leader in online marketing and e-commerce business platforms. Acting as an integral consultant to Canada's leading cannabis association, The Cannabis Trade Alliance of Canada (CTAC), Reid has provided valuable advocacy to all levels of government on strategies for a legal cannabis framework in Canada. A husband and father of two beautiful girls, Reid enjoys time with family and the outdoors.



James Poelzer | Director,
Chief Business Development Officer

Spearheading business development for Ascent, James has been essential in targeting and executing cannabis license applications in multiple jurisdictions and cultivating strategic partnerships and investment opportunities for Ascent. Having successfully secured licenses in Canada, Oregon and Nevada, James always stays ahead of the curve, pursuing the next opportunity for Ascent. James has a Bachelor of Business Administration, Joint Major with Psychology, from Simon Fraser University.



Karim Lalani | Chief Legal Officer

Karim has practiced corporate finance & securities law, mergers & acquisitions, and corporate & commercial law. Key areas of expertise include Canadian, US and cross-border private and public debt and equity offerings, take-over bids and mergers and acquisitions transactions. Karim received his LL.B. from the University of Ottawa and was admitted to the British Columbia Bar and the Ontario Bar in 1996, and the Washington State Bar in 2007.



Chris Lee | Chief Marketing Officer

With a passion for delivering strategic and creative solutions for brands, Chris has over 20 years of marketing agency experience strategizing and developing brand campaigns for international companies including Google, Pepsi, Best Buy, Adidas, Toyota, Scion and XM Satellite Radio. Chris earned a Bachelor of Arts (B.A.) with a major in Communications and a minor in Psychology from Simon Fraser University and a diploma in Internet Marketing from the UBC Sauder School of Business.




Blair Jordan | Chief Financial Officer

Blair was previously VP Corporate Development with Ascent, and brings a wealth of knowledge and experience to the Ascent team as a former investment banker with many years of Canadian and international experience, and particular expertise in financing and M&A transactions. He was most recently Managing Director of Investment Banking at Echelon Wealth Partners Inc., and before that, spent nearly ten years with Credit Suisse in London, New York and Tokyo. Before joining Credit Suisse, he was a securities lawyer with Bennett Jones LLP in Calgary. He holds an MBA from the Booth School of Business at the University of Chicago, and an LLB from the University of British Columbia.

ASCENT | ESTABLISHED BRANDS

Ascent has developed and sold brands and products since inception, developing strong recognition with consumers in brand-legal jurisdictions.



Ascent's Brand Portfolio

Ascent is currently selling products in Oregon and Nevada, and expects to begin sales of products in Canada in October 2018. Ascent's brands already have strong recognition in open-brand markets.

ASCENT | INTERNATIONAL PLATFORM

Ascent is pursuing international growth opportunities in a variety of cannabis legal jurisdictions, leveraging existing brands, processes and experience.



CANADIAN MARKET



ADULT USE



MEDICAL



FLOWER • PRE-ROLLS • VAPORIZER PENS
GEL-CAPS • TINCTURES/ BOTTLES

- Focused product range
- Mass production
- Cost-competitive manufacturing



EUROPE



COPENHAGEN, DENMARK



TINCTURES/BOTTLES • GEL-CAPS

- Focused product range
- Medical market
- Leverage quality, cost advantage with planned EU GMP certification



US MARKET



OREGON



NEVADA




EDIBLES • TINCTURES/BOTTLES • GEL-CAPS
DISTILLATE FLOWER • PRE-ROLLS

- Wide product range
- Capture shelf space
- Build brand awareness

ASCENT | PROVEN EXECUTION RECORD

With a strong record of execution, Ascent's management team is confident in delivering further growth.

2017










Note:

*Representative timeline - subject to change.

ASCENT | LICENSED CAMPUSES PROVIDE INDUSTRIAL SCALE

Ascent's global campuses position the company for large-scale growth.

					
	AGRIMA LABS Pitt Meadows, BC 	AGRIMA BOTANICALS Maple Ridge, BC 	AGRIMA MEADOWS Pitt Meadows, BC 	SWEET OREGON Portland, OR 	SWEET NEVADA Las Vegas, NV 
BUILDING SIZE	40,000 Sq. Ft. Custom Retrofit Production & Processing Facility	25,000 Sq.Ft. Custom Built Indoor Cultivation Facility	600,000 Sq.Ft. Automated Cultivation Greenhouse	7,000 Sq. Ft. Custom Retrofit Production & Processing Facility	37,500 Sq.Ft. Custom Retrofit Cultivation, Production & Processing Facility
LAND SIZE	1 acre	5 acres	25 acres	0.25 acre	1.5 acres
CULTIVATION ANNUAL CAPACITY	Extraction Only	2,000 kg high-grade dried flower	60,000 kg low to-mid-grade dried flower	Extraction Only	3,000 kg high-grade dried flower
PRODUCTION ANNUAL CAPACITY *	6,000 kg of extracted & formulated oil Commercial Kitchen	1,500 kg of extracted & formulated oil	Cultivation Only	1,500 kg of extracted & formulated oil Commercial Kitchen	3,000 kg of extracted & formulated oil Commercial Kitchen
OPERATIONS STATUS	Commencing operations Q4 2018**	Operational since 2011	Targeted Completion of Acquisition – Q4 2018 Targeted Commencement of Operations – Q1 2019**	Operational Since September 2017	Phase 1 (2,500 square feet) Operational - Targeted Full Operations Commencement - Q1 2019
DISTRIBUTION REACH	Q4 2018	Q3 2018	Q1 2019	Currently selling in approximately 1100 dispensaries – 10 product lines with 40 SKUs	Currently selling in approximately 15 dispensaries – 3 product lines with 20 SKUs
TOTALS 710,000 sq.ft. capacity 65 million grams cannabis output 12 million grams annual oil output					

Notes:

*Production refers to the extraction of cannabis oil (in kg), and the preparation of products which contain cannabis oil and/or cannabis flower.

**Pending licensing.

ASCENT | INDUSTRIAL SCALE

Ascent expects to be one of the only LPs with mass production vaporizer pen and flower packaging machines.

Vaporizer Pens

Ascent's planned vaporizer pen production machine is expected to be able to produce in excess of 1,000,000 vaporizer pens per month at initial production rates, with additional expansion possible.

Flower Packing


Ascent's automated flower packing machine is able to process 2,400 packages per hour, filling to within one-hundredth of a gram, with minimal labor required.

Gel-caps and Tincture

Ascent is planning to build a fully automated capsule production line, capable of producing 2,000,000 bottles per month (30 capsules per bottle).

Pre-Rolled Joints

Ascent is developing a fully automated pre-roll line, capable of producing more than 1,000,000 units per month.



ASCENT | RESEARCH & DEVELOPMENT

As leaders in cannabis extraction and product development, Ascent's multi-jurisdictional team sets the standard for innovative extraction processes and consumer products.

- **Intellectual Property Generation** – Agrima Scientific Corp. is the R&D division of Ascent, focused on developing commercially viable products, services and intellectual property, leading to the creation of patents, trademarks and trade secrets, enhancing Ascent's ability to protect it's competitive position and generate sustainable revenues.
- **Key Research Partners** - Agrima Scientific Corp. is entering its fifth year of a research agreement with Simon Fraser University's Department of Biological Sciences, funding Master of Science students to engage in cannabis-focused research. Agrima Scientific recently engaged Simon Fraser University scientists to commence a pre-clinical trial designed to explore potential therapeutic benefits of cannabinoids for various debilitating medical conditions.
- **Strong Brand Development** – Ascent ties the creation of scientific intellectual property to the development of brands covering both products and services, effectively generating revenue from Ascent's research focus.


Agrima Scientific's Primary Research:



- Patent Protected Delivery Mechanisms and Formulations for Cannabis
- Extraction and Formulations
- Plant Tissue Culture Propagation
- Breeding and Genetics
- Scanning Electron Microscopy
- Plant Pathology and Pest Control
- Analytical Testing and Plant Diagnosis
- Pre-clinical Trials of Cannabinoid-based Therapies

ASCENT | KEY PARTNERS

Ascent has partnered with global experts to accelerate growth.



1

Aurora Cannabis Inc.

- Up to 20,000 kg/year raw cannabis

British Columbia Liquor Distribution Board

- Initial, small-scale purchase order

Ontario Cannabis Retail Corporation

- Initial, small-scale purchase order

2

Simon Fraser University

- Five years of cannabis focused research funding for Masters students
- Pre-clinical trial exploring potential therapeutic benefits of cannabinoids for various debilitating medical conditions

3

ANTG (Australia)*

- Up to 10,000 kg/year

The Hydroponics Company (Australia)*

- Various genetics

Craft Growers (British Columbia)**

*Letter of Intent

**Discussions ongoing

ASCENT | TECHNOLOGY LEADERSHIP

Ascent has invested heavily in technology to drive business growth and global expansion.

- Ascent is currently developing a customized Enterprise Resource Planning (ERP) software system to facilitate global expansion.
- The ERP system provides a backbone for compliance and financial analysis at Ascent, and is configured to provide easy capability growth in the future.
- Ascent management believes the ERP system will provide Ascent with the ability to scale rapidly and develop cutting edge business intelligence, providing a distinct competitive advantage for Ascent as it continues to grow.





ASCENT | GROWTH CATALYSTS

CANADA

Production Capacity Expansion - Ascent is adding additional cultivation and manufacturing space, with the acquisition of Agrima Meadows, a 600,000 square foot greenhouse, closing Q3 2018, with expected operational readiness in Q4 2018. Agrima Labs, Ascent's manufacturing facility, is expected to be ready to commence operations in Q4 2018.

Licensing - Ascent anticipates receiving both a Sales Licence and second site LP licenses for Agrima Meadows and Agrima Labs over the next several months.

USA

Licensed Operations Expansion - Sweet Cannabis is actively pursuing cultivation and extraction opportunities in various states, with a strong focus on California opportunities.

Hemp/CBD - Ascent has invested in Agtech Scientific, a Canadian corporation based in Kentucky that develops hemp-derived, CBD-based medicinal formulas to be used in various health and wellness applications. Agtech is partnered with major universities to produce clinical research supporting the benefits of CBD-based products.

EUROPE

Denmark – Agrima Botanicals ApS, a wholly-owned Danish subsidiary of Ascent, has applied for a level 10 controlled drug license in Denmark, and made applications under the medical cannabis pilot program with the Danish Medicine Agency, including applications for the approval of eight cannabis derivative products (comprised of four formulations of tinctures and four formulations of gel caps) that are currently in formal review.

European Distribution – Agrima ApS recently secured a lease for a good manufacturing practice (GMP) pharmaceutical handling facility in Denmark, which will serve as a key distribution center for its medicinal product in Europe.

ASCENT | CAPITAL STRUCTURE

SHARE COUNT (MILLIONS)		
Outstanding Shares	315m	
Warrants	105m	
Convertible Note	11m	
Fully Diluted Shares, before ESOP	431m	
ESOP-Feb 2018 to 2022	32m	
Fully Diluted Shares as at September 2018	462m	
Management, Founders and Directors	109m	25% of Fully Diluted, before ESOP
Other Employees	8m	2% of Fully Diluted, before ESOP
Total Shares owned by Employees and Founders	117m	27% of Fully Diluted, before ESOP

TOTAL
SHAREHOLDERS:
900+

FOUNDER
AND BOARD
OWNERSHIP:
25%



Ascent
PRODUCT CATALOGUE



MEDICAL

Agrima

A better quality of life.

Agrima has been at the forefront of the cannabis movement since long before it became topical. As a leader in therapeutic cannabis, our name can be traced back to not only cannabis and agriculture, but to the Sanskrit word “Agrima” — meaning “Leader”. We aim to empower ‘the agrima’ within each and every patient, equipping them to lead a higher quality of life. Naturally.

The initial product offering will include skillfully grown high grade flower, whole plant vegan gel caps and alcohol-free supercritical CO2 extracted tincture. Agrima prides itself on having a portfolio of formulations available to consumers; providing safe, quality therapeutic cannabis to as many people as possible.



CONVENIENCE

Toko

Stay Curious

When you come together in ceremony and laughter you become kin; you become toko. Even if a companion is in no way related, a complete stranger, your toko becomes your brother. And so when you share Toko in your circle, it's a gesture with arms open wide. A welcoming. And this overture we extend to you by offering a carefully curated cannabis collection.

Through careful strain selection, meticulous extraction processes and extensive dosing knowledge we've developed the best tasting vaporizer pens that arrive in the most stylish, convenient and easy to use forms.

The Ascent logo is located in the bottom left corner of the page. It features the word "Ascent" in a serif font, with a thin, curved line arching over the letters "scent".

CANNABIS PURIST

The Quarry

Expertly crafted cannabis

At the Quarry we select only premium cannabis and create products that challenge the status quo. We question everything, and never, ever settle. The Quarry collection has curated, top shelf cannabis products including the finest flower, pre-rolled joints, and 100% pure extracts and concentrates. Each product is rigorously tested for quality, safety, and purity to ensure you catch a smooth ride every time. Jump In. You won't look back.



EDIBLES

Grace Notes

The finest gourmet cannabis infused edibles available on the market.

In the 1930s the early pioneers of jazz were avowed users of cannabis, “hepcats.” It gave them stamina to play through long nights. They also knew that gage lengthened time—allowing them to play the improvisations between written notes... the grace notes.

At Grace Notes Edibles we honour their story, the idea of lengthening time, fostering community, and creating something beautiful. Each note is eloquently crafted from natural ingredients in our artisanal kitchen.





EDIBLES

Taffy Notes

Delicious cannabis infused candy and sweets.

Dedicated to quality ingredients and consistent dosing, Taffy Notes edibles uses 100% pure cannabis oil, free of residual solvents, ensuring only the cleanest, most reliable treat is produced.



NUTRACEUTICAL

NU

Bonjour, we're Nu. As in the French word meaning nude, naked, natural or more fittingly, au naturel. Our raison d'être – is to set free the power of therapeutic cannabis.

Nu's premium line of therapeutic cannabis infusions have been developed, formulated, and dare we say, carefully crafted by scientists and researchers. Our products are pure, natural, and sans pesticides and other harmful chemicals.

By using the highest standards of cannabis processing and production anywhere, we deliver the cleanest, most reliable therapeutic cannabis products on the market. That's the naked truth.

TESTING/ANALYTICAL

GreenScreen Plant Sex ID Kit

DNA based cannabis genetic screening and testing kits for commercial and home-grower applications.

Enables growers to determine the sex of their seedlings in a fraction of the time compared to traditional sex determination methods, providing significant value to any size cultivation facility.

GreenScreen is currently servicing clients in 28 US states and 10 countries around the world.

GreenScreen is developing new Kits that offer cultivators pathology screening and cannabinoid potency tests.



LEGAL DISCLAIMER | FORWARD LOOKING STATEMENTS

Legal Disclaimer

This presentation provides an overview of the business of Ascent Industries Corp. (“Ascent” or the “Company”). This presentation has been prepared for informational purposes only. No representation, warranty or undertaking, express or implied, is made and no responsibility or liability is accepted by the Company, as to the accuracy or completeness of the information contained herein. There are certain risks inherent in an investment in the securities of Ascent that prospective investors should carefully consider before investing in the securities of the Company, including, but not limited to, those set forth below under “Forward-Looking Information”. An investment in the Company is highly speculative and involves significant risks, including the possible loss of the entire amount invested. This document is not, and under no circumstances is to be construed as, an advertisement or a public offering of the securities of the Company in Canada or the United States. No securities commission or similar authority in Canada or the United States has reviewed or in any way passed upon this document or the merits of the securities in the Company and any representation to the contrary is an offence.

This presentation is not an offer to sell securities, and we are not soliciting an

offer to buy securities, in any jurisdiction. The securities have not been registered with the U.S. Securities and Exchange Commission.

Forward-Looking Information

This presentation contains “forward-looking information” including “future-oriented financial information” and “financial outlooks”, within the meaning of applicable securities laws. This forward-looking information is based on certain assumptions and expectations of management in light of currently available information and historical data, which are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those anticipated. While management believes its assumptions and expectations are reasonable, investors are strongly cautioned that there can be no assurance that Ascent will achieve the results predicted, within the periods predicted or at all. To the extent any forward-looking information in this presentation constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable securities laws, such information is being provided to demonstrate the potential of Ascent and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Actual results may differ materially from what the Company currently

expects and what is projected in this document. Such information is presented for illustrative purposes only.

When used herein, the words “anticipate,” “estimate,” “plan,” “believe,” “expect,” “forecast,” “project,” or variations or symbols of such words and similar expressions are intended to identify forward-looking information. Factors that may cause actual results to differ materially from those anticipated include, but are not limited to: (i) the Company’s expectations regarding revenues, expenses and anticipated costs; future production costs and capacity; (iii) the completion of the acquisition of Agrima Meadows, (iv) actual performance of the Company’s business and operations; (v) the ability to renew the Company’s licenses from Health Canada; (vi) sufficient working capital and the Company’s ability to raise additional financing going forward; (vii) industry growth trends, including with respect to projected and actual industry sales; (viii) the legalization of cannabis for recreational use in Europe, Canada and the United States, including federal, provincial and state regulations pertaining thereto and the timing thereof and the Company’s intentions to participate in such markets, if and when such market is legalized; (ix) the impact of general business and economic conditions; and (x) whether the key personnel will continue their employment with the Company.

All of the forward-looking information in this presentation is qualified by these cautionary statements and we cannot assure you that the results or developments anticipated by management will be realized or even if realized, will have the expected consequences to, or effects on, us or our business, prospects, financial condition, results of operations or cash flows. Readers are cautioned not to place undue reliance on the forward-looking information in making any investment decision. Forward-looking information made in this presentation applies only as of the date of this presentation. While we may elect to update forward-looking statements from time to time, we specifically disclaim any obligation to do so, even in the light of new information or future events, unless otherwise required by applicable securities laws.

U.S. Federal and State Cannabis Laws Advisory and Notice

Certain of Ascent’s operations are in the United States, including in the State of Oregon and the State of Nevada. Ascent’s operations in the United States are governed by both US federal and state laws, and the intersection of US federal and state cannabis laws is a uniquely complex and rapidly-changing area of law.

LEGAL DISCLAIMER | FORWARD LOOKING STATEMENTS (cont'd.)

Federal Law Advisory: While certain U.S. states have enacted legislation regulating the production and sale of cannabis, cannabis continues to be categorized as a controlled substance under the Controlled Substances Act (the “CSA”) in the United States and as such, may be in violation of federal law in the United States. Unless and until the U.S. Congress amends the CSA with respect to cannabis (and as to the timing or scope of any such potential amendments there can be no assurance), there is a risk that federal authorities may enforce current federal law, which may adversely affect the current and future operations of Ascent in the United States. On January 4, 2018, U.S. Attorney General Jeff Sessions rescinded the U.S. Department of Justice’s guidance to U.S. federal prosecutors that state-regulated cannabis industries should generally not be a prosecutorial priority. Although the rescission of this guidance does not necessarily indicate that marijuana industry prosecutions are now affirmatively a priority for the DOJ, there can be no assurance that the federal government will not enforce such laws in the future. Furthermore, while the Rohrabacher-Blumenaur Appropriations Amendment currently remains in effect such that federal funding to prosecute cannabis offences of individuals in compliance with state laws remains limited, the continued reauthorization of the Rohrabacher-Blumenaur Appropriations Amendment remains uncertain. Together, these federal laws and policies may provide some protections from federal government

enforcement actions for those persons and businesses who act in strict compliance with local and state cannabis laws in the United States. Compliance with all applicable state and local laws is therefore of paramount importance and failure to do so can have serious ramifications under both state and federal laws of the United States.

State Law Advisory: The laws of the various states in the United States that allow medical cannabis and/or non-medical adult use cannabis are varied and rapidly-changing. The laws in states that allow medical cannabis or adult use cannabis may still provide for state criminal prosecution, asset forfeiture, civil injunctions, and other forms of enforcement or penalty for failure to strictly follow the laws of state and local governments.

While we plan to operate in strict compliance with the above US federal and state legal requirements, there can be no assurance we will always operate in strict compliance with applicable legal requirements under US federal or state laws or that we will not be deemed to operate outside of these requirements, which could materially adversely the business of the Company.

Canadian Cannabis Laws Advisory and Notice

The Canadian Federal Government has regulated medical use and commercial activity involving cannabis and recently Bill

C-45, which proposes the enactment of the Cannabis Act (Canada), to regulate the production, distribution and sale of cannabis for unqualified adult use, with a target implementation date of no later than July 1, 2018. On February 6, 2018, Canada’s Public Safety Minister, Ralph Goodale, announced that while Bill C-45 was still on schedule to receive royal assent in July 2018, implementation of various aspects of the regime, including preparing markets for retail sales, could take another eight to twelve weeks from the date Bill C-45 receives royal assent. On March 19, 2018, Health Canada announced the results of its public consultation on the proposed regulatory approach to cannabis, which included specific requirements for packaging and labeling of cannabis products, including mandatory health warning messages. There can be no assurance that the legalization of recreational cannabis by the Canadian Federal Government will occur as specifically proposed under the Cannabis Act (Canada) or at all, and the legislative framework pertaining to the provincial recreational cannabis market is uncertain.

This presentation is confidential and is being provided to you solely for your information and may not be reproduced, in whole or in part, in any form or forwarded or further distributed to any other person. Any forwarding, distribution or reproduction of this presentation in whole

or in part is unauthorized. By accepting and reviewing this presentation, you acknowledge and agree (i) to maintain the confidentiality of this presentation, the information contained herein and all other information received in connection with your evaluation of a potential investment in the Company, (ii) to protect such information in the same manner you protect your own confidential information, which shall be at least a reasonable standard of care and (iii) to not utilize any of the information contained herein or otherwise received except to assist with your evaluation of a potential investment in the Company. You will be liable for any damage caused by or resulting from any unauthorized disclosure or use of the information contained herein.

Note: All funds are in Canadian dollars. US funds are converted at 1.27.

CONTACT US

Philip Campbell | Chairman & Chief
Executive Officer
philip@ascentindustries.com

Blair Jordan | Chief Financial Officer
blair.jordan@ascentindustries.com

Jon Bey | Vice President, Investor Relations
Jon.bey@ascentindustries.com

Please visit us at:
ascentindustries.com



Ascent Industries Corp.
260-22592 Lougheed Hwy.
Maple Ridge, BC V2X 0T5
Canada